Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of denosumab in postmenopausal osteoporosis
NL-OMON30869Phase 3Withdrawn
- Sponsor
- Amgen
- Start
- Oct 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of denosumab in postmenopausal osteoporosis, sponsored by Amgen. Primary endpoint: Long-term safety and tolerability. Planned start Oct 2007; status: withdrawn.
02
Drugs
denosumab
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on NL-OMON30869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON30869.